Glioma-initiating cells (GICs) are implicated in tumor heterogeneity and therapeutic resistance of GBM. Here we demonstrate that the BRG1 subunit of the SWI/SNF chromatin remodeling complex plays critical roles in maintaining GICs in a stem-like state. Furthermore, we have identified a novel mechanism by which BRG1 regulates expression of TXNIP, which is a redox regulator and also negatively regulates glycolysis. We found that BRG1 regulates TXNIP through a STAT3-dependent pathway. We demonstrate that BRG1 plays a critical role in the drug resistance of GICs, and in GIC-induced tumorigenesis. Thus, the BRG1-STAT3-TXNIP axis is a potential therapeutic target in GBM.
This study provides a comprehensive evaluation of the safety and efficacy of mesenchymal stem cell therapy for acute myocardial infarction and ischemic heart disease. Results from this systematic review suggest that this cellular therapy may be safe. A well‐designed, adequately powered randomized controlled trial with rigorous adverse event reporting and comprehensive assessment of cardiac function is warranted. This will help establish a definitive risk‐benefit profile of mesenchymal stromal cell therapy for ischemic heart disease.
New study highlights the exciting potential for autologous micro‐fragmented adipose tissue in the treatment of osteoarthritis in patients following an animal trial